非小细胞肺癌患者血浆中miR-26b的表达及其临床意义  

The expression and clinical significance of circulating miR-26b in patients with non small cell lung cancer

作　　者：吴唐维[1] 胡绘 李晓怡 刘水逸[1] 张天竺 陈卫群[1] 卢忠心[1] WU Tangwei;HU Hui;LI Xiaoyi;LIU Shuiyi;ZHANG Tianzhu;CHEN Weiqun;LU Zhongxin(Department of Clinical Laboratory,Central Hospital of Wuhan Affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei 430014,China)

机构地区：[1]华中科技大学同济医学院附属武汉中心医院检验科,湖北武汉430014

出　　处：《国际检验医学杂志》2018年第16期1968-1971,共4页International Journal of Laboratory Medicine

基　　金：湖北省自然科学基金重点项目(2015CFA078);武汉市黄鹤英才计划;武汉市卫生计生委资助项目(WX11A03;WX14B10;WX15A12);武汉市中心医院院内青年基金项目(YQ14A01;YQ15A03)

摘　　要：目的探讨微小RNA-26b(miR-26b)在非小细胞肺癌(NSCLC)患者血浆中的表达水平及其在肺癌辅助诊断及疗效监测中的作用。方法收集80例NSCLC患者(肺癌组,其中腺癌48例、鳞癌32例,临床分期Ⅰ/Ⅱ期、Ⅲ期和Ⅳ期分别有30、24、26例)及45例健康人(对照组)的血浆,应用实时荧光定量PCR(FQPCR)检测miR-26b水平。80例肺癌患者中有50例收集到配对的治疗前后血浆,通过FQ-PCR检测上述50例肺癌患者治疗前后血浆中的miR-26b水平。结果对照组血浆miR-26b相对表达量为33.03±19.6,肺癌组为11.57±9.41,肺癌组血浆miR-26b显著低于对照组(t=6.908,P<0.01)。肺腺癌和肺鳞癌患者血浆miR-26b水平分别为11.32±8.56、12.03±9.92,均低于对照组(t=6.841、6.162,P<0.01);肺腺癌和肺鳞癌患者之间血浆miR-26b水平无显著差异(P>0.05)。肺癌组中,Ⅰ/Ⅱ期、Ⅲ期和Ⅳ期患者血浆miR-26b相对表达量分别为15.26±11.17、9.47±7.04、9.37±6.66,Ⅰ/Ⅱ期、Ⅲ期和Ⅳ期血浆miR-26b水平均低于对照组(t值分别为4.987、7.235、7.394,P<0.01);Ⅲ期和Ⅳ期患者血浆miR-26b水平低于Ⅰ/Ⅱ期患者(t值分别为2.32、2.43,P<0.05);Ⅲ期与Ⅳ期患者之间血浆miR-26b水平无显著差异(P>0.05)。50例肺癌患者治疗前后血浆miR-26b相对表达量分别为10.68±8.18、18.69±10.71,治疗后血浆miR-26b水平较治疗前显著升高(t=-4.855,P<0.01)。结论 miR-26b在肺癌患者血浆中明显降低,并且血浆miR-26b水平与肺癌分期密切相关,血浆miR-26b在治疗后显著升高,血浆miR-26b水平有可能作为肺癌辅助诊断及疗效监测的新指标。Objective To investigate circulating miR-26 blevel in human serum for use as a biomarker for stratification and monitoring efficacy in NSCLC.Methods The plasma from 80 cases of non small cell lung cancer（NSCLC）（lung cancer group）,including 48 cases of adenocarcinoma,32 cases of squamous cell carcinoma,30 cases in stage Ⅰ/Ⅱ,24 cases in stage Ⅲ and 26 cases in stage Ⅳ,and 45 healthy people（control group）were collected.Quantitative RT-PCR was performed to evaluate the expression of circulating miR-26 b.50 of 80 patients with lung cancer had matched plasma samples before and after treatment.The plasma levels of microarray-26 bwere detected by FQ-PCR.Results The relative expression of miR-26 bin the control group was 33.03±19.6,while that in lung cancer group was 11.57±9.41,and the plasma miR-26 bin lung cancer group was significantly lower than that in the control group（t=6.908,P〈0.01）.The levels of plasma miR-26 bin the adenocarcinoma group and thesquamous cell carcinoma group were 11.32±8.56 and 12.03±9.92,which were lower than those in the control group（t=6.841,6.162,P〈0.01）,and there was no statistical significance in the levels of plasma miR-26 bin the adenocarcinoma group and thesquamous cell carcinoma group（P〉0.05）.The relative expressions of circulating miR-26 blevel in stage Ⅰ/Ⅱ（15.26±11.17）,stage Ⅲ（9.47±7.04）and stageⅣ（9.37±6.66）were lower than that in the control group（t=4.987,7.235,7.394,P〈0.01）.The circulating miR-26 blevels in stageⅢ and stage IV were lower than that in stageⅠ/Ⅱ（t=2.32,2.43,P〈0.05）,and the there was no statistical significance in the levels of plasma miR-26 bbetween the patients in stageⅢ and stageⅣ（P〉0.05）.Furthermore,the expression level of miR-26 bin the post-operative plasma of 50 lung cancer patients（18.69±10.71）was significantly increased when compared to their preoperative plasma（10.68±8.18）（t=-4.855,P〈0.01）.Conclusion The circulating miR-26 blevel was significantly reduce

关 键 词：非小细胞肺癌 miR-26b 诊断 疗效监测 

分 类 号：R734.2[医药卫生—肿瘤]